BusinessPhoto: NDTV BusinessZota Health Care Q2 Shows Recovery; Nirmal Bang Cuts Target Price
Zota Health Care's Q2 FY27 results showed sequential operating recovery with consolidated revenue up 54.6% YoY to Rs 200 crore, driven by Davaindia's 76.2% growth to Rs 170 crore. EBITDA turned positive at Rs 3.1 crore due to lower marketing costs but was offset by higher employee expenses. Nirmal Bang retained its Buy rating but trimmed the target price to Rs 1,670, expecting 62% CAGR revenue growth through FY26–FY28.
NDTV Business·


